JPH11279081A - Composition containing bitter material - Google Patents
Composition containing bitter materialInfo
- Publication number
- JPH11279081A JPH11279081A JP10080923A JP8092398A JPH11279081A JP H11279081 A JPH11279081 A JP H11279081A JP 10080923 A JP10080923 A JP 10080923A JP 8092398 A JP8092398 A JP 8092398A JP H11279081 A JPH11279081 A JP H11279081A
- Authority
- JP
- Japan
- Prior art keywords
- bitter
- composition
- bitterness
- aspartyl
- dimethylbutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 239000000463 material Substances 0.000 title abstract 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 229960001948 caffeine Drugs 0.000 claims abstract description 7
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims abstract description 6
- 229940024606 amino acid Drugs 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 4
- 239000011707 mineral Substances 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 4
- 235000001258 Cinchona calisaya Nutrition 0.000 claims abstract description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960000948 quinine Drugs 0.000 claims abstract description 3
- 235000019658 bitter taste Nutrition 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 8
- 239000004475 Arginine Substances 0.000 abstract description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract description 3
- 229960000310 isoleucine Drugs 0.000 abstract description 3
- 150000004702 methyl esters Chemical class 0.000 abstract description 3
- 239000004474 valine Substances 0.000 abstract description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 2
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 2
- 230000006866 deterioration Effects 0.000 abstract description 2
- 229940003871 calcium ion Drugs 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Seasonings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、各種苦味物質を含
有する経口用医薬品及び食品に関する。TECHNICAL FIELD The present invention relates to an oral medicine and a food containing various bitter substances.
【0002】[0002]
【従来の技術とその問題点】苦味を有する物質に関する
苦味の除去、抑制方法についてはこれまでに様々な取り
組みがなされている。特に、医薬品の分野に関しては、
その有効成分に苦味を有する物が多く、苦味の抑制法に
ついては製剤の技術において重要な問題となっている。2. Description of the Related Art Various approaches have been made to remove and control bitterness of substances having bitterness. Especially in the field of pharmaceuticals,
Many of the active ingredients have a bitter taste, and the method of suppressing the bitter taste is an important problem in pharmaceutical technology.
【0003】苦味の抑制方法については、固形剤の場
合、糖衣、コーティング剤の使用、カプセル化、包接化
合物の使用が行われている。また、液剤に関しては、固
形剤と比較し、液体の中で安定なコーティングが困難で
あるため、高濃度の糖あるいは、有機酸の添加、フレー
バーの添加が行われている。また最近では、苦味抑制機
能を持つレシチンの添加による苦味の抑制方法も知られ
ている。[0003] Regarding the method of suppressing bitterness, in the case of a solid preparation, sugar coating, use of a coating agent, encapsulation, use of an inclusion compound are performed. Further, as for liquid preparations, it is difficult to perform stable coating in liquids as compared with solid preparations, so that high-concentration sugars or organic acids are added, and flavors are added. Recently, a method of suppressing bitterness by adding lecithin having a bitterness suppressing function is also known.
【0004】しかしながら、これらの方法では、充分な
苦味の抑制ができなかったり、また水溶液での保存中
に、成分の分解等により効果が弱くなったりするという
問題点がある。また、糖類の添加においては、かなり高
濃度での添加となるので糖尿病等でカロリー制限のある
患者には適さないという問題点がある。特に乳幼児、小
児の場合、錠剤や顆粒状の製剤の服用が困難であるため
液剤や使用時に溶解するドライシロップの処方が多く、
液剤での苦味の抑制方法は大きな課題となっている。[0004] However, these methods have problems that bitterness cannot be sufficiently suppressed, and that the effect is weakened due to decomposition of components during storage in an aqueous solution. In addition, the addition of saccharides has a problem that it is not suitable for a patient having a calorie restriction due to diabetes or the like, since the addition is performed at a considerably high concentration. Especially in the case of infants and children, it is difficult to take tablets and granular preparations.
A method of suppressing bitterness in a liquid preparation has been a major issue.
【0005】食品においては、蛋白質の加水分解物から
得られるペプチド、アミノ酸の苦味、果汁等の苦味や栄
養強化の目的で添加されるミネラル等の苦味、収れん味
が様々な形態の食品で問題になっている。食品中の苦味
を抑制する方法としては、甘味剤を添加する方法、有機
酸の添加、吸着体を用いて苦味物質を除去する方法、包
接化合物を用いる方法、酵素処理する方法等がある。ま
た、医薬品と同様にレシチンを添加する方法もある。In foods, the bitterness of peptides and amino acids obtained from protein hydrolysates, the bitterness of fruit juices and the like, the bitterness of minerals added for the purpose of nutritional enhancement, and the astringency are problematic in foods of various forms. Has become. Methods for suppressing bitterness in food include a method of adding a sweetener, a method of adding an organic acid, a method of removing a bitter substance using an adsorbent, a method of using an inclusion compound, and a method of enzymatic treatment. Also, there is a method in which lecithin is added in the same manner as pharmaceuticals.
【0006】しかし、これらの方法を用いても、苦味物
質によって効果があまりなかったり充分に効果が得られ
ない場合がある。However, even when these methods are used, there are cases where bitter substances have little or no effect.
【0007】また、甘味剤、例えば糖類添加の場合、糖
尿病等のカロリー摂取制限のある患者の場合は不向きで
ある。一方、高甘味度甘味料の添加は添加量が微量です
むためカロリーの問題はないものの、甘味の質により、
グリチルリチンでは、先味の苦味を抑制することができ
ない、あるいは、水溶液中で分解されることにより効果
が減少する等の問題がある。[0007] In addition, when a sweetener such as a saccharide is added, it is unsuitable for a patient who has restricted calorie intake such as diabetes. On the other hand, the addition of high-intensity sweeteners does not require a small amount of addition, so there is no problem of calories, but depending on the quality of sweetness,
Glycyrrhizin has a problem that the bitterness of the first taste cannot be suppressed, or the effect is reduced by being decomposed in an aqueous solution.
【0008】[0008]
【発明が解決しようとする課題】組成物の物性、特に液
状組成物において、粘度等の物性に悪影響を与えず、且
つ、褐変等の保存中の品質劣化を伴うことなく、高い苦
味抑制効果を維持する物質を見いだし、苦味の抑制され
た良好な呈味質の医薬、食品を得る。SUMMARY OF THE INVENTION In a liquid composition, a high bitterness-suppressing effect can be obtained without adversely affecting the physical properties such as viscosity and the like, and without accompanying deterioration in quality such as browning during storage. A substance to be maintained is found, and a medicine or food having a good taste with suppressed bitterness is obtained.
【0009】[0009]
【課題を解決するための手段】本発明者らは、上記課題
解決につき鋭意検討した結果、ジメチルブチル−α−L
−アスパルチル−Lフェニルアラニンメチルエステルの
併用により、物性等に悪影響をもたらすことなく、苦味
を顕著に抑制し得るとの知見に至り本発明を完成した。Means for Solving the Problems The inventors of the present invention have conducted intensive studies on solving the above problems and found that dimethylbutyl-α-L
It has been found that the combined use of -aspartyl-L-phenylalanine methyl ester can significantly suppress bitterness without adversely affecting physical properties and the like, and completed the present invention.
【0010】[0010]
【発明の実施の形態】本発明の対象となる苦味物質は、
アルギニン、バリン、ロイシン、イソロイシン、メチオ
ニン、ヒスチジン、オルニチン、プロリン、リジンその
他の苦味を有するアミノ酸、苦味を有するペプチド、キ
ニーネ、カフェイン、カルシウムイオンとその他のミネ
ラル等である。或いは、各種生薬等の苦味物質含有物も
当然対象となる。上記苦味物質は、一種でも二種以上の
組み合わせでもよい。組成物に占める苦味物質の割合は
苦味物質により異なるが、0.001〜2%が一般的で
ある。BEST MODE FOR CARRYING OUT THE INVENTION
Arginine, valine, leucine, isoleucine, methionine, histidine, ornithine, proline, lysine and other bitter amino acids, bitter peptides, quinine, caffeine, calcium ions and other minerals. Alternatively, naturally, substances containing bitter substances such as various crude drugs are also targeted. The bitter substance may be one kind or a combination of two or more kinds. The proportion of the bitter substance in the composition varies depending on the bitter substance, but is generally 0.001 to 2%.
【0011】これらの苦味物質と併用するジメチルブチ
ル−α−L−アスパルチル−Lフェニルアラニンメチル
エステルの組成物中に占める割合は、組成物の種類によ
っても異なるが、使用時、溶液として調整したときに0.
002〜0.020ミリモル/100gである。0.002ミリモル/100g未満であ
るとその効果が充分認められず、0.020ミリモル/100g以上で
あると甘味が強すぎて飲料としての嗜好性に問題があ
る。The proportion of dimethylbutyl-α-L-aspartyl-Lphenylalanine methyl ester in the composition used in combination with these bitter substances varies depending on the type of the composition. 0.
002-0.020 mmol / 100 g. If the amount is less than 0.002 mmol / 100 g, the effect is not sufficiently recognized. If the amount is more than 0.020 mmol / 100 g, the sweetness is too strong and there is a problem in the palatability as a beverage.
【0012】本発明の苦味抑制法は、液体で最もその効
果が認められるが、その形態は、用事液体であれば、粉
末、顆粒、その他錠剤状その他の固形状、ペースト等如
何なる形状でも構わない。The effect of the bitterness suppression method of the present invention is most recognized when the liquid is used, but the form may be any shape such as powder, granules, tablets, other solids, and pastes as long as the liquid is business liquid. .
【0013】苦味物質と併用するジメチルブチル−α−
L−アスパルチル−Lフェニルアラニンメチルエステル
の添加時期・方法に特に規制はない。Dimethylbutyl-α- used in combination with a bitter substance
There is no particular restriction on the timing and method of adding L-aspartyl-L-phenylalanine methyl ester.
【0014】次に実施例により、本発明を更に説明す
る。尚、ジメチルブチル−α−L−アスパルチル−Lフ
ェニルアラニンメチルエステルを以下「NM」と略記す
る。Next, the present invention will be further described with reference to examples. Here, dimethylbutyl-α-L-aspartyl-L phenylalanine methyl ester is abbreviated as “NM” below.
【0015】[0015]
【実施例】<実施例1>アミノ酸溶液(2%アルギニン
溶液)に、ジメチルブチル−α−L−アスパルチル−L
フェニルアラニンメチルエステル、アスパルテームを下
記の濃度添加した溶液を2日室温放置したのち、熟練さ
れたパネル4名により官能評価を行い苦味の等価濃度を
求めた。結果を表1に示す。尚、苦味の等価濃度は無水
カフェイン水溶液の濃度で示す。<Example 1> Dimethylbutyl-α-L-aspartyl-L was added to an amino acid solution (2% arginine solution).
After a solution containing phenylalanine methyl ester and aspartame at the following concentrations was allowed to stand at room temperature for 2 days, sensory evaluation was performed by four skilled panels to determine the equivalent concentration of bitterness. Table 1 shows the results. The equivalent concentration of bitterness is indicated by the concentration of an anhydrous caffeine aqueous solution.
【0016】[0016]
【表1】 [Table 1]
【0017】<実施例2>混合アミノ酸溶液(ロイシ
ン、バリン、イソロイシン)2%溶液に、ジメチルブチ
ル−α−L−アスパルチル−Lフェニルアラニンメチル
エステル、グリチルリチン、ショ糖を加えた溶液につ
き、1日室温放置し熟練されたパネル4名で苦味の等価
濃度を求めた。結果を表2に示す。尚、苦味の等価濃度
は無水カフェイン水溶液の濃度で示す。<Example 2> A solution obtained by adding dimethylbutyl-α-L-aspartyl-Lphenylalanine methyl ester, glycyrrhizin, and sucrose to a 2% mixed amino acid solution (leucine, valine, isoleucine) solution at room temperature for one day The equivalent concentration of bitterness was determined by four expert panels that were left standing. Table 2 shows the results. The equivalent concentration of bitterness is indicated by the concentration of an anhydrous caffeine aqueous solution.
【0018】[0018]
【表2】 [Table 2]
【0019】<実施例3>硫酸キニーネ(0.0039g/100
g)、無水カフェイン(0.205g/100g)、クエン酸第一鉄(0.
05g/100g)、乳酸カルシウム(0.15g/100g)、チアミン塩
酸塩(0.5g/100g)各々につき、ジメチルブチル−α−L
−アスパルチル−Lフェニルアラニンメチルエステル
(0.013ミリモル/100g)、グリチルリチン(0.472ミリモル/100g)を
加えた溶液につき、1日室温放置し熟練されたパネル4
名で苦味の等価濃度を求めた。結果を表3に示す。尚、
苦味の等価濃度は無水カフェイン水溶液の濃度で示す。<Example 3> Quinine sulfate ( 0.0039g / 100)
g ), anhydrous caffeine (0.205 g / 100 g), ferrous citrate (0.
05g / 100g), calcium lactate (0.15g / 100g), thiamine hydrochloride (0.5g / 100g), dimethylbutyl-α-L
-Aspartyl-L phenylalanine methyl ester
(0.013 mmol / 100 g) and glycyrrhizin (0.472 mmol / 100 g) were added to the solution.
The equivalent concentration of bitterness was determined by name. Table 3 shows the results. still,
The equivalent concentration of bitterness is indicated by the concentration of the anhydrous caffeine aqueous solution.
【0020】[0020]
【表3】 [Table 3]
フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 31/52 A61K 31/52 33/06 33/06 38/00 37/02 Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 31/52 A61K 31/52 33/06 33/06 38/00 37/02
Claims (2)
ーネ、カフェイン、ミネラル等の苦味物質一種以上とジ
メチルブチル−α−L−アスパルチル−Lフェニルアラ
ニンメチルエステルを含有することを特徴とする苦味物
質含有組成物。1. A bitter substance-containing composition comprising at least one bitter substance such as amino acids, peptides, quinine, caffeine, and minerals having bitter taste and dimethylbutyl-α-L-aspartyl-L-phenylalanine methyl ester. Stuff.
物質含有組成物。2. The composition containing a bitter substance according to claim 1, wherein the composition is a liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10080923A JPH11279081A (en) | 1998-03-27 | 1998-03-27 | Composition containing bitter material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10080923A JPH11279081A (en) | 1998-03-27 | 1998-03-27 | Composition containing bitter material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH11279081A true JPH11279081A (en) | 1999-10-12 |
Family
ID=13731958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10080923A Pending JPH11279081A (en) | 1998-03-27 | 1998-03-27 | Composition containing bitter material |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH11279081A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001010236A1 (en) * | 1999-08-11 | 2001-02-15 | The Nutrasweet Company | CONFECTIONERY FOOD PRODUCTS SWEETENED WITH N-[N-(3,3-DIMETHYLBUTYL)-1-α-ASPARTYL]-L-PHENYLALANINE METHYL ESTER |
| JP2001112417A (en) * | 1999-10-14 | 2001-04-24 | Ezaki Glico Co Ltd | Tablet candy |
| WO2001028590A3 (en) * | 1999-10-19 | 2008-01-03 | Nutrasweet Co | PHARMACEUTICAL COMPOSITIONS CONTAINING N-[N-(3,3-DIMETHYLBUTYL)-1-α-ASPARTYL]-L-PHENYLALANINE METHYL ESTER |
-
1998
- 1998-03-27 JP JP10080923A patent/JPH11279081A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001010236A1 (en) * | 1999-08-11 | 2001-02-15 | The Nutrasweet Company | CONFECTIONERY FOOD PRODUCTS SWEETENED WITH N-[N-(3,3-DIMETHYLBUTYL)-1-α-ASPARTYL]-L-PHENYLALANINE METHYL ESTER |
| JP2001112417A (en) * | 1999-10-14 | 2001-04-24 | Ezaki Glico Co Ltd | Tablet candy |
| WO2001028590A3 (en) * | 1999-10-19 | 2008-01-03 | Nutrasweet Co | PHARMACEUTICAL COMPOSITIONS CONTAINING N-[N-(3,3-DIMETHYLBUTYL)-1-α-ASPARTYL]-L-PHENYLALANINE METHYL ESTER |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4726269B2 (en) | Oral solution | |
| US20100119692A1 (en) | Modifying undesirable tastes | |
| EP0566638A1 (en) | Flavor stable zinc acetate compositions for oral absorption | |
| JP4051717B2 (en) | Biotin-containing oral solution | |
| JP2003235512A (en) | Amino acid-containing composition improved in taste | |
| JP2003274896A (en) | Reducer of bitterness of bitter amino acid and its use | |
| KR20020018675A (en) | Method and Composition for Masking Mineral Taste | |
| JP2005336078A (en) | Masking agent | |
| EP1878350B1 (en) | Water-containing food | |
| JPH11279081A (en) | Composition containing bitter material | |
| JP2000217547A (en) | Amino acid-containing composition having reduced bitter taste | |
| JP4929628B2 (en) | Zinc-containing oral solution | |
| JPH07118150A (en) | Oral medicine having adjusted taste comprising branched amino acid as active ingredient | |
| JP5162812B2 (en) | Zinc-containing composition for oral administration | |
| JP5586816B2 (en) | Composition containing zinc compound | |
| JPH10287551A (en) | Oral solution with improved unpleasant taste of amino acids | |
| JP5098198B2 (en) | Copper compound composition | |
| JP5044957B2 (en) | Copper compound composition | |
| JP5546089B2 (en) | Composition containing zinc compound | |
| WO2000021390A1 (en) | Bitterness relieving agent | |
| JP2002173442A (en) | Anti-fatigue composition | |
| JP4815798B2 (en) | Copper-containing composition for oral administration | |
| JP5167594B2 (en) | Composition for internal use liquid containing copper compound | |
| JPH1036252A (en) | Belladonna (total) alkaloid-containing oral liquid | |
| JP2000044469A (en) | Oral solution |